Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Risk of CKD in biopsy-proven metabolic dysfunction-associated steatotic liver disease.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2026
Same author

Implementation of evidence-based alcohol policies to reduce alcohol-related harm and liver disease to advance public health in Europe.

The Lancet regional health. Europe·2026
Same author

Safety and Efficacy of Neoadjuvant Therapy in Cholangiocarcinoma: Protocol for a Systematic Review and Meta-Analysis.

JMIR research protocols·2026
Same author

Complete immunosuppression withdrawal after liver transplantation: An International Multicenter Study.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

Chronic kidney disease in cirrhosis: a study of inpatients from a global perspective.

Gut·2026
Same author

MASLD, diabetes and PMOS across the female life stages.

Diabetologia·2026
Same journal

Inter and intra-observer agreement for the LST Classification in Large (>2cm) Colorectal Laterally Spreading Tumours.

The American journal of gastroenterology·2026
Same journal

The Safety and Effectiveness of Early Anti-Tumor-Necrosis-Factor Therapy for Penetrating Crohn's Disease Complications in Children.

The American journal of gastroenterology·2026
Same journal

Calendar of Courses, Symposiums and Conferences.

The American journal of gastroenterology·2026
Same journal

Continuing Medical Education Questions: September 2024.

The American journal of gastroenterology·2026
Same journal

Continuing Medical Education Questions: September 2024.

The American journal of gastroenterology·2026
Same journal

Continuing Medical Education Questions: September 2024.

The American journal of gastroenterology·2026
See all related articles

Related Experiment Video

Updated: May 14, 2026

Development of an Ethanol-induced Fibrotic Liver Model in Zebrafish to Study Progenitor Cell-mediated Hepatocyte Regeneration
10:42

Development of an Ethanol-induced Fibrotic Liver Model in Zebrafish to Study Progenitor Cell-mediated Hepatocyte Regeneration

Published on: May 13, 2016

9.3K

Defining Risk in Alcohol-Associated Liver Disease Using the Model for End-Stage Liver Disease.

Richard Parker1,2, Guru Aithal3, Michael Allison4

  • 1Leeds Liver Unit, St James's University Hospital, Leeds, United Kingdom.

The American Journal of Gastroenterology
|July 17, 2025
PubMed
Summary
This summary is machine-generated.

This study describes the long-term outcomes of alcohol-associated liver disease (ALD), finding the Model for End-Stage Liver Disease (MELD) score effectively predicts liver-related mortality and liver transplantation risk across disease severity.

Keywords:
alcohol associated liver diseasenatural historyrisk prediction

More Related Videos

The Murine Choline-Deficient, Ethionine-Supplemented CDE Diet Model of Chronic Liver Injury
07:27

The Murine Choline-Deficient, Ethionine-Supplemented CDE Diet Model of Chronic Liver Injury

Published on: October 21, 2017

11.9K
Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
09:44

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Published on: November 27, 2019

10.3K

Related Experiment Videos

Last Updated: May 14, 2026

Development of an Ethanol-induced Fibrotic Liver Model in Zebrafish to Study Progenitor Cell-mediated Hepatocyte Regeneration
10:42

Development of an Ethanol-induced Fibrotic Liver Model in Zebrafish to Study Progenitor Cell-mediated Hepatocyte Regeneration

Published on: May 13, 2016

9.3K
The Murine Choline-Deficient, Ethionine-Supplemented CDE Diet Model of Chronic Liver Injury
07:27

The Murine Choline-Deficient, Ethionine-Supplemented CDE Diet Model of Chronic Liver Injury

Published on: October 21, 2017

11.9K
Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
09:44

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Published on: November 27, 2019

10.3K

Area of Science:

  • Hepatology
  • Internal Medicine
  • Clinical Prognostics

Background:

  • Alcohol-associated liver disease (ALD) is a significant cause of illness and death.
  • Existing prognostic scores for ALD often lack long-term predictive accuracy.
  • Understanding the natural history and long-term risks of ALD is crucial for patient management.

Purpose of the Study:

  • To describe the natural history of alcohol-associated liver disease (ALD) over the long term.
  • To evaluate and define risk prediction for morbidity and mortality in ALD, including non-liver causes.
  • To assess the predictive performance of prognostic scores like MELD in a large ALD cohort.

Main Methods:

  • Utilized the WALDO cohort, comprising 734 patients with biopsy-proven ALD.
  • Assessed prognostic scores using dynamic area under the curve and C-index.
  • Derived and validated risk estimates for the Model for End-Stage Liver Disease (MELD) in an external cohort.

Main Results:

  • Over a median of 4.9 years, 240 patients died from liver disease or underwent liver transplantation (LT), and 114 died from non-liver causes.
  • Liver-related death or LT incidence varied significantly by ALD severity: 47% in decompensated cirrhosis, 40% in alcohol-associated hepatitis, 13% in compensated cirrhosis, and 7.4% in patients without cirrhosis.
  • The Model for End-Stage Liver Disease (MELD) score demonstrated the best predictive accuracy for mortality/LT at 1 year (AUC 0.853), performing similarly to MELD3.0 and Child-Turcotte-Pugh score.

Conclusions:

  • The study elucidates the natural history of alcohol-associated liver disease.
  • The Model for End-Stage Liver Disease (MELD) score effectively defines risks for various outcomes across the spectrum of ALD.
  • Risk stratification using MELD scores is validated and applicable for long-term prognostication in ALD patients.